Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on discovering and developing small-molecule therapies for virology and immunology. Its pipeline includes EDP-514, a phase 1b program for chronic hepatitis B infection; zelicapavir and EDP-323, both in phase II development for respiratory syncytial virus; EDP-235, a phase II candidate for human coronaviruses; EDP-978 for chronic spontaneous urticaria; and EPS-3903 for atopic dermatitis. The company also works on antiviral protease inhibitors, including glecaprevir, for chronic hepatitis C infection. Enanta maintains a collaborative development and license agreement with Abbott Laboratories covering HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Incorporated in 1995, Enanta is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ENTA
|
$10.53
|
-15.3% Downside
|
Fair
|
$21.83
|
75.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
3.6x
|
5.5x
|
361.7 M
|
332.3 M
|
34.0%
|
77.3%
|
-0.9
|
58.4%
|
